Stay updated with breaking news from Functional Class. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating...
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 -- Liquidia Corporation announced today...
Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent...
MORRISVILLE, N.C., Aug. 10, 2023 -- Liquidia Corporation today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss... -Today at 06:01 am- MarketScreener
No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...